



**THE FIRST NON-HORMONAL
NEUROKININ B (NK1) ANTAGONIST**
INDICATED IN THE TREATMENT OF VMS
ASSOCIATED WITH MENOPAUSE^{1-3*}

CONSIDER VEOZAH

ONE DOSE, ONE TABLET, ONCE A DAY

45 mg orally once daily, with or without food

VEOZAH (fezolinetant film-coated tablets) is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.¹



Actual size shown.
Tablet is 7 mm in diameter.

Recommended dosing & administration¹



45 mg orally once daily, with or without food

Take VEOZAH with liquids at about the same time every day, and swallow whole. Do not cut, crush, or chew tablets. VEOZAH tablets do not contain gluten or lactose.[†]



Missed dose guidance

If a dose is missed or not taken at the usual time, patients should take the missed dose as soon as possible, unless there is less than 12 hours before the next scheduled dose. Return to the regular schedule the following day.



Special populations

Hepatic impairment

- VEOZAH is contraindicated in individuals with cirrhosis.
- VEOZAH is not recommended for use in individuals with Child-Pugh Class B (moderate) chronic hepatic impairment.
- VEOZAH has not been studied in individuals with Child-Pugh Class C (severe) chronic impairment and is not recommended in this population.

Renal impairment

- VEOZAH is contraindicated in individuals with severe[‡] renal impairment.
- VEOZAH has not been studied in individuals with end-stage renal disease and is contraindicated in this population.[§]

Please see the Product Monograph for complete dosing and administration information.

* Comparative clinical significance unknown.

† Clinical significance unknown.

‡ eGFR less than 30 mL/min/1.73 m².

§ eGFR less than 15 mL/min/1.73 m².

eGFR: estimated glomerular filtration rate.

DOSING CONSIDERATIONS¹

Monitoring hepatic function

Baseline hepatic function (Before starting VEOZAH) Month 1 Month 2 Month 3 Month 6 Month 9

While using VEOZAH: Continue monitoring



When to monitor

- Baseline (prior to starting VEOZAH)
- Monthly for the first 3 months, at 6 months and 9 months



What to monitor

Perform bloodwork to evaluate hepatic function and assess for injury:

- Serum ALT
- Serum AST
- Serum ALP
- Serum bilirubin (total and direct)

Clinical action

Proceed with caution if:	• ALT or AST is between $>1.5 \times \text{ULN}$ and $<2 \times \text{ULN}$	
Do not start VEOZAH if:	• ALT or AST $\geq 2 \times \text{ULN}$ or	• Total bilirubin $\geq 2 \times \text{ULN}$
Discontinue VEOZAH if:	• Transaminase elevations $>5 \times \text{ULN}$ and/or	• Transaminase elevations $>3 \times \text{ULN}$ and total bilirubin $>2 \times \text{ULN}$
If transaminase elevations $\geq 3 \times \text{ULN}$ occur:	• Perform more frequent follow-up hepatic laboratory tests until resolution	• Exclude alternative causes of hepatic laboratory test elevations

Advise patients to discontinue VEOZAH immediately and seek medical attention including hepatic laboratory tests if they experience the below signs or symptoms that may suggest liver injury.

- New onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale feces, dark urine, or abdominal pain.

For appropriate use of VEOZAH,
ensure all hepatic safety requirements are met

Consult the Product Monograph at veozahmonograph.ca for important information relating to:

- Contraindications in patients with known cirrhosis, severe renal impairment or end-stage renal disease, using concomitant moderate or strong CYP1A2 inhibitors, with known or suspected pregnancy, hypersensitive to the drug or to any ingredient in the formulation.
- Relevant warnings and precautions regarding incidence of other malignancies, known or previous breast cancer or estrogen-dependent malignancies, endometrial hyperplasia and endometrial carcinoma, patients with moderate or severe hepatic impairment (Child-Pugh Class B or C), hepatic transaminase elevation and hepatotoxicity, hepatic function and injury monitoring, and breast-feeding.
- Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

The Product Monograph is also available by calling **1-888-338-1824**.

Scan or visit
Veozahhcp.ca to access
additional resources



ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ULN: upper limit of normal.

REFERENCES: **1.** VEOZAH Product Monograph. Markham, ON: Astellas Pharma Canada, Inc. **2.** The North American Menopause Society (NAMS). *Menopause*. 2023;30(6):573-590. **3.** Data on file. First and only claim. **4.** Data on file. Ingredient information.

All trademarks are the property of their respective owners.
© 2026 Astellas Pharma Inc. or its affiliates.
MAT-CA-VEO-2026-00050 03/26

